NeuroSense Therapeutics Ltd. NRSN
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.33M | 1.33M | 1.09M | 1.09M | 685.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.20M | 3.20M | 2.35M | 2.35M | 1.77M |
| Operating Income | -3.20M | -3.20M | -2.35M | -2.35M | -1.77M |
| Income Before Tax | -3.21M | -3.21M | -2.35M | -2.35M | -1.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.21M | -3.21M | -2.35M | -2.35M | -1.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.21M | -3.21M | -2.35M | -2.35M | -1.80M |
| EBIT | -3.20M | -3.20M | -2.35M | -2.35M | -1.77M |
| EBITDA | -3.19M | -3.19M | -2.34M | -2.34M | -1.77M |
| EPS Basic | -2.51 | -2.51 | -1.85 | -1.85 | -1.66 |
| Normalized Basic EPS | -1.57 | -1.57 | -1.16 | -1.16 | -1.04 |
| EPS Diluted | -2.51 | -2.51 | -1.85 | -1.85 | -1.66 |
| Normalized Diluted EPS | -1.57 | -1.57 | -1.16 | -1.16 | -1.04 |
| Average Basic Shares Outstanding | 1.28M | 1.28M | 1.27M | 1.27M | 1.08M |
| Average Diluted Shares Outstanding | 1.28M | 1.28M | 1.27M | 1.27M | 1.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |